Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Multicenter, Randomized, Active-Controlled, Open-label Study to Evaluate the Efficacy and Safety of Zanubrutinib in Patients With Primary Membranous Nephropathy

NCT05707377 is registered in ClinicalTrials.gov with BeOne Medicines as lead sponsor.

NCT NCT05707377
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05707377 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Multicenter, Randomized, Active-Controlled, Open-label Study to Evaluate the Efficacy and Safety of Zanubrutinib in Patients With Primary Membranous Nephropathy
Lead sponsor
BeOne Medicines
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
April 17, 2023
Completion date
October 31, 2027
Enrollment
178 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

primary membranous nephropathy